^Arnerić SP, Roetker A, Long JP, Mott J, Barfknecht CF (June 1982). "Effects of semirigid methoxamine analogs on vascular smooth muscle: studies of methoxy-2-aminotetralin and 2-aminoindane derivatives". Archives Internationales de Pharmacodynamie et de Thérapie. 257 (2): 263–73. PMID7114973.
^Arnerić SP, Long JP (May 1984). "Evidence that a novel dopamine receptor agonist, RDS-127 [2-di-n-propylamino-4,7-dimethoxyindane] has some centrally mediated cardiovascular actions". The Journal of Pharmacy and Pharmacology. 36 (5): 318–21. doi:10.1111/j.2042-7158.1984.tb04382.x. PMID6145768. S2CID24354158.
^Rezaki YE, Ilhan M (1991). "Evaluation of alpha-adrenoceptor agonistic activity of RDS-127 (2-di-n-propylamino-4,7-dimethoxyindane) in rabbit and rat aortae". Archives Internationales de Pharmacodynamie et de Thérapie. 310: 76–86. PMID1685313.
^Sahin I, Ilhan M (1988). "The antimuscarinic activity of a dopamine receptor agonist (RDS-127) differentiates M2-muscarinic receptors of heart, ileum and trachea in guinea-pig". Archives Internationales de Pharmacodynamie et de Thérapie. 296: 163–72. PMID2907277.
^Sahin I, Tuncer M, Ilhan M (March 1990). "Dopamine receptor agonists, N,N-dipropyl-2-aminotetralin (TL-68) and 2-di-n-propylamino-4,7-dimethoxyindane (RDS-127) antagonize oxotremorine-induced tremors by antimuscarinic action in mice". Archives Internationales de Physiologie et de Biochimie. 98 (1): 7–9. doi:10.3109/13813459009115730. PMID1692697.
^Arnerić SP, Roetker A, Long JP (September 1982). "Potent anorexic-like effects of RDS-127 (2-di-n-propylamino-4,7-dimethoxyindane) in the rat: a comparison with other dopamine-receptor agonists". Neuropharmacology. 21 (9): 885–90. doi:10.1016/0028-3908(82)90080-6. PMID6897285. S2CID12005863.
^Kwong LL, Smith ER, Davidson JM, Peroutka SJ (October 1986). "Differential interactions of "prosexual" drugs with 5-hydroxytryptamine1A and alpha 2-adrenergic receptors". Behavioral Neuroscience. 100 (5): 664–8. doi:10.1037/0735-7044.100.5.664. PMID2877677.